Dr. Isaacman founded PHD Biosciences in 2008, and currently serves as the Chief Executive Officer (CEO) where he manages the preclinical and clinical therapeutic programs. He is an expert in the development and commercialization of topical and systemic drug products; has been responsible for the invention and management of collaborative efforts that have led to the commercialization of several globally distributed drug- and non-drug products; and since 2011 has been the Principal Investigator on 19 of PHD’s grants. He is also a Visiting Scholar in the Chemistry department at New York University. He received his Ph.D. in organic chemistry from New York University, and M.S. and B.S. degrees in chemistry and biochemistry from Stony Brook University.
Stephanie J Hachey, Ph.D. is the Founder, CEO and CSO of ImmunoTarget Therapeutics, an innovative biotechnology company developing highly personalized immunotherapies to treat cancer and other diseases. Stephanie holds an M.S. in Biomedical and Translational Science and a Ph.D. in Molecular Biology and Biochemistry from UC Irvine. Stephanie is an accomplished molecular biologist, demonstrating a strong publication record and proven ability to secure funding, with a passion for bringing life-saving therapies to the clinic.
Damian Wheeler is the Co-Founder and CEO of Translucence Biosystems. As a neuroscientist with more than 25 years of research experience, both in academia and in drug discovery, Damian’s focus is on developing and commercializing the next-generation technologies to advance neuroscience research and accelerate CNS drug discovery. During his Ph.D. studies at McGill University and Post-Doc at Stanford, Damian became a leading expert in the signaling mechanisms by which neuronal activity activates gene transcription. He then spent 9 years at Dart NeuroScience developing cognition-enhancing drugs that engage these mechanisms. In mid-2018, Damian co-founded Translucence Biosystems with UCI professor Sunil Gandhi and his MD/PhD student, Ricardo Azevedo to generate tools and technologies for next-generation 3D histology.
Dr. Schmid has significant experience at the interface of technology and commercialization, She was an Assistant Professor at Princeton University, and then served as a senior executive in a series of biotechnology companies. She reviewed proposals for many years on NIH SBIR study sections. Currently, she is a consultant for the Small Business Development Center based at UCI, and for UCI Beall Applied Innovation. She is a member of the Tech Coast Angels and participates in the Orange County-TCA biomedical pre-screening panel. Dr. Schmid is an elected Fellow of the American Academy of Microbiology and the American Institute for Medical and Biological Engineering. She earned her PhD in biology from the University of Utah and her BS degree from SUNY Albany.
Do you have a great company in the bioscience or medtech industry? Do you need wet-lab and/or fabrication space to develop and test your product?
